VT104 is an inhibitor of TEAD auto-palmitoylation that effectively blocks the palmitoylation of TEAD1 and TEAD3 proteins. It selectively inhibits YAP/TAZ-TEAD-promoted gene transcription and exhibits strong antitumor and anti-proliferative effects.

ZX703 is a proteolysis targeting chimera (PROTAC), that is a degrader of GPX4 through the ubiquitin-proteasome and the autophagy-lysosome with a DC50 of 0.315 µM. It induces the accumulation of lipid reactive oxygen species (ROS), thereby inducing ferroptosis cancer cells.

VT104 is an inhibitor of TEAD auto-palmitoylation that effectively blocks the palmitoylation of TEAD1 and TEAD3 proteins. It selectively inhibits YAP/TAZ-TEAD-promoted gene transcription and exhibits strong antitumor and anti-proliferative effects.

VT104 is an inhibitor of TEAD auto-palmitoylation that effectively blocks the palmitoylation of TEAD1 and TEAD3 proteins. It selectively inhibits YAP/TAZ-TEAD-promoted gene transcription and exhibits strong antitumor and anti-proliferative effects.

ZX703 is a proteolysis targeting chimera (PROTAC), that is a degrader of GPX4 through the ubiquitin-proteasome and the autophagy-lysosome with a DC50 of 0.315 µM. It induces the accumulation of lipid reactive oxygen species (ROS), thereby inducing ferroptosis cancer cells.

ZX703 is a proteolysis targeting chimera (PROTAC), that is a degrader of GPX4 through the ubiquitin-proteasome and the autophagy-lysosome with a DC50 of 0.315 µM. It induces the accumulation of lipid reactive oxygen species (ROS), thereby inducing ferroptosis cancer cells.

HRS-4642 is a selective inhibitor of KRAS G12D with a Kd value of 0.083 nM. It exhibits robust anti-cancer activity against KRAS G12D-mutant cancers both in vitro and in vivo.

ZX703 is a proteolysis targeting chimera (PROTAC), that is a degrader of GPX4 through the ubiquitin-proteasome and the autophagy-lysosome with a DC50 of 0.315 µM. It induces the accumulation of lipid reactive oxygen species (ROS), thereby inducing ferroptosis cancer cells.

HRS-4642 is a selective inhibitor of KRAS G12D with a Kd value of 0.083 nM. It exhibits robust anti-cancer activity against KRAS G12D-mutant cancers both in vitro and in vivo.

HRS-4642 is a selective inhibitor of KRAS G12D with a Kd value of 0.083 nM. It exhibits robust anti-cancer activity against KRAS G12D-mutant cancers both in vitro and in vivo.